Phase II clinical trial, multicenter, open, uncontrolled, to evaluate the effectiveness of the combination of sorafenib and bevacizumab in the treatment of patients with advanced and/or metastatic neuroendocrine tumors [ENSAYO CLINICO DE FASE II, MULTICENTRICO, ABIERTO, NO CONTROLADO PARA EVALUAR LA EFICACIA DE LA COMBINACION DE SORAFENIB Y BEVACIZUMAB EN EL TRATAMIENTO DE PACIENTES CON TUMOR NEUROENDOCRINO AVANZADO Y/O METASTASICO]

Trial Profile

Phase II clinical trial, multicenter, open, uncontrolled, to evaluate the effectiveness of the combination of sorafenib and bevacizumab in the treatment of patients with advanced and/or metastatic neuroendocrine tumors [ENSAYO CLINICO DE FASE II, MULTICENTRICO, ABIERTO, NO CONTROLADO PARA EVALUAR LA EFICACIA DE LA COMBINACION DE SORAFENIB Y BEVACIZUMAB EN EL TRATAMIENTO DE PACIENTES CON TUMOR NEUROENDOCRINO AVANZADO Y/O METASTASICO]

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Sep 2013

At a glance

  • Drugs Bevacizumab (Primary) ; Sorafenib (Primary)
  • Indications Neuroendocrine tumours
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Aug 2011 New trial record
    • 01 Sep 2009 Status changed from recruiting to completed according to results published in the European Journal of Cancer.
    • 01 Apr 2009 Recruitment completed according to Results published in the European Journal of Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top